Brief: Dsm-firmenich Q3 Results Beat Consensus, 2026 Growth Outlook Lifted
BRIEF-Dsm-firmenich Q3 Results Beat Consensus, 2026 Growth Outlook Lifted Nov 4 (Reuters) - DSM-Firmenich AG DSFIR.AS:
DSM-FIRMENICH REPORTS Q3 2026 TRADING UPDATE
Q3 TOTAL SALES €2.37 BILLION (DSM-PROVIDED CONSENSUS: €2,355 MILLION)
Q3 ADJUSTED EBITDA €482 MILLION (DSM-PROVIDED CONSENSUS: €478 MILLION)
Q3 ORGANIC SALES GROWTH 5% (DSM-PROVIDED CONSENSUS: 4.7%)
Q3 ADJUSTED EBITDA MARGIN 20.4% (DSM-PROVIDED CONSENSUS: 20.3%)
FY 2026 OUTLOOK: LFL SALES GROWTH INCREASED TO AROUND 5% (PREVIOUSLY 2-4%)
REITERATES OUTLOOK 2026 FOR ADJUSTED EBITDA MARGIN AT AROUND 20%
Source text: ID: nGNE2HYpVS
Further company coverage: DSFIR.AS
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00; ))
Recent news on DSM-Firmenich AG
See all newsAnalysis: Brazil's corn ethanol boom accelerating growth of feedlot beef
Top of the Street: Hensoldt, Unilever, Evonik, dsm-firmenich, IMCD, AAK
Weak US sentiment hurts dietary supplement sales, offsetting broader growth, Novonesis CEO says
Europe Research Roundup: Asos, Erste Group, SCHOTT pharma
Dsm-firmenich raises growth outlook in line with expectations (updated)